Laboratory study demonstrates scalable androstenedione synthesis via modular metabolic engineering in Mycobacterium neoaurum, suggesting an efficient biomanufacturing route for steroid drugs.
Androstenedione (AD) is an important precursor for the synthesis of corticosteroids, sex hormones, and other high-value steroid pharmaceuticals. Microbial conversion of phytosterols provides a sustainable route for AD production, but current production levels remain insufficient for practical industrial application. In this study, a modular metabolic engineering strategy was developed to improve AD biosynthesis from phytosterols in Mycobacterium neoaurum LY-2. Competing C19 and C22 steroid pathways were first blocked to attenuate AD degradation, generating the AD-accumulating strain Mbn12 with a titer of 5.14 g/L. Sterol catabolic flux was then enhanced by relieving transcriptional repression and improving acetyl-CoA and propionyl-CoA utilization, which increased AD production to 6.08 g/L. To support high-flux sterol oxidation, cofactor regeneration and oxidative stress resistance were further strengthened, raising AD production to 6.67 g/L. Finally, moderate cell envelope remodeling improved substrate transport and increased AD production to 6.98 g/L. The final engineered strain Mbn30 produced 20.55 g/L AD from 30 g/L phytosterols in a 5 L fermenter, representing a 48.6% improvement over Mbn12. This work provides a scalable engineering framework for AD production and offers guidance for the microbial manufacture of other steroid intermediates.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: